ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$34.70
+3.49%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$33.78
From 52W high−17.01%
Volume6.30M
Market cap$25.06B
P/E (TTM)—
P/S (TTM)3327.7x
Div yield—
Key dataOct 19, 2026
Open
$33.78
From 52W high
−17.01%
Volume
6.30M
Market cap
$25.06B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−76.7x
P/E (TTM)
—
RSI (14)
45.5
MomentumView details →
1D Return
+3.49%
YTD Return
+60.32%
SummaryUpdated Jun 1, 2026
Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical and healthcare technology company founded in 2014 and headquartered in London, United Kingdom. The company went public in December 2020 and operates as a holding company that develops and commercializes innovative medicines across multiple therapeutic areas. Roivant has built a portfolio of subsidiary companies, each focused on specific drug development programs, and has successfully brought several products to market while maintaining a robust pipeline of clinical-stage assets targeting various diseases including autoimmune disorders, dermatological conditions, and rare diseases.
Similar companies
Latest newsMore news →
Roivant reported strong efficacy for its pipeline drug mosliciguat in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD).39d agoRoivant Sciences announced that its experimental lung disease drug met the main goal in a mid-stage study, causing its shares to surge 21.1% in pre-market trading.41d agoRoivant and its subsidiary Pulmovant announced that results from the Phase 2 PHocus study of Mosliciguat in PH-ILD will be presented at the ERS International Congress 2026 on September 8, 2026.42d ago